Black Seed Cholesterol Randomized Trial: What the Evidence Says

Quick Answer

Black Seed Cholesterol Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Quality assessment, including risk of bias, was performed using the Jadad checklist. [Dashti S (2026); evidence level 1]
• BACKGROUND: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age and one of the important causes of infertility due to a lack of ovulation. [Dashti S (2026); evidence level 1]
• Additionally, the risk of disease development is significantly increased by comorbidities such as obesity, type 2 diabetes, and metabolic syndrome. [Fic Weronika (2026); evidence level 3]
• Excessive enlargement of the necrotic core relative to the thickness of the fibrous cap increases the risk of plaque rupture and thrombus formation. [Fic Weronika (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For black seed cholesterol randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Dashti S (2026). Herbal compounds in the treatment of polycystic ovary syndrome: an updated systematic review.. DOI: 10.1186/s13048-026-02030-z. PMCID: PMC13041406. PMID: 41761211. https://pmc.ncbi.nlm.nih.gov/articles/PMC13041406/
• Fic Weronika (2026). Thymoquinone in Atherosclerosis: A Multi-Target Nutraceutical Modulating Inflammation, Oxidative Stress, and Lipid Metabolism. DOI: 10.3390/nu18091480. PMCID: PMC13165017. PMID: 42124081. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13165017/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.